San Diego-based clinical oncology firm Sorrento Therapeutics said today that it has named a new board director. Sorrento Therapeutics said it named Daniel Levitt, the current Executive Vice President and Chief Medical Officer of CytRx, to its board of directors. Levitt has more than 28 years of experience in the drug development and biopharmaceuticals area. Levitt replaces Ernst-Guenter Afting, Ph.D., who has stepped down from the company's board to focus on his consulting activities in Europe, according to the company.
Top NewsMonday, February 3, 2014
Sorrento Therapeutics Names New Board Member